Tumour biomarkers in heart failure: Is there a role for CA-125?

European Journal of Heart Failure

Volumn 13, Issue 6, 2011, Pages 579-583

  Yilmaz, Mehmet Birhan ^a,c   Nikolaou, Maria ^b,c   Solal, Alain Cohen ^c,d  

^a CUMHURIYET UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c HÔPITAL LARIBOISIÈRE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

CA 125; Heart failure; Tumour markers

Indexed keywords

CA 125 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; NATRIURETIC PEPTIDE RECEPTOR A; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; AORTA STENOSIS; CARDIAC PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; ENDOCARDITIS; FOLLOW UP; HEART ATRIUM PRESSURE; HEART ATRIUM SEPTUM DEFECT; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; MITRAL VALVE STENOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; REVIEW; TRICUSPID VALVE STENOSIS;

CA-125 ANTIGEN; HEART FAILURE; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79957810943     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfr022     Document Type: Review

References (64)

1. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, Oates JA, Peck CC, Schooley RT, Spilker BA, Woodcock J, Zeger SL. Biomarkers and surrogate endpoints preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89-95. (Pubitemid 32225406)
2. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358:2148-2159.
3. Varol E, Ozaydin M, Dogan A, Kosar F. Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail 2005;7:840-843. (Pubitemid 41125903)
4. Faggiano P, D'Aloia A, Antonini-Canterin F, Vizzardi E, Nicolosi GL, Cas LD. Tumour markers in chronic heart failure. Review of the literature and clinical implications. J Cardiovasc Med (Hagerstown) 2006;7:573-579. (Pubitemid 44350491)
5. Chen YX, Wang XQ, Fang CF, Wang JF, Tang LJ. Value of BNP and tumour marker CA125 in patients with heart failure. Acta Cardiol 2008;63:501-506.
6. Blokkebak-Poulsen J, Mogensen O, Mogensen B. Tissue polypeptide-specific antigen (TPS) as tumour marker in epithelial ovarian cancer. Acta Oncol 1997; 36:433-435. (Pubitemid 27298565)
7. Yi Y, Li B, Wang Z, Sun H, Gong H, Zhang Z. CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squa-mous cell carcinoma. Biomarkers 2009;14:480-485.
8. Feldman SA, Eiden LE. The chromogranins: their roles in secretion from neuro-endocrine cells and as markers for neuroendocrine neoplasia. Endocr Pathol 2003;14:3-23. (Pubitemid 36605679)
9. Nagele H, Bahlo M, Klapdor R, Rodiger W. Fluctuations of tumor markers in heart failure patients pre and post heart transplantation. Anticancer Res 1999;19: 2531-2534. (Pubitemid 29392407)
10. Faggiano P, D'Aloia A, Brentana L, Bignotti T, Fiorina C, Vizzardi E, Dei Cas L. Serum levels of different tumour markers in patients with chronic heart failure. Eur J Heart Fail 2005;7:57-61. (Pubitemid 40092492)
11. Rosjo H, Husberg C, Dahl MB, Stridsberg M, Sjaastad I, Finsen AV, Carlson CR, Oie E, Omland T, Christensen G. Chromogranin B in heart failure: a putative cardiac biomarker expressed in the failing myocardium. Circ Heart Fail 2010;3: 503-511.
12. Rosjo H, Masson S, Latini R, Flyvbjerg A, Milani V, La Rovere MT, Revera M, Mezzani A, Tognoni G, Tavazzi L, Omland T. GISSI-HF investigators. Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial. Eur J Heart Fail 2010;12:549-556.
13. Tota B, Angelone T, Mazza R, Cerra MC. The chromogranin A-derived vasosta-tins: new players in the endocrine heart. Curr Med Chem 2008;15:1444-1451. (Pubitemid 351997794)
14. Angelone T, Quintieri AM, Brar BK, Limchaiyawat PT, Tota B, Mahata SK, Cerra MC. The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 2008;149:4780-4793.
15. Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 2010;29: 2893-2904.
16. Whitehouse C, Solomon E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecol Oncol 2003;88:S152-S157.
17. O'Brien TJ, Tanimoto H, Konishi I, Gee M. More than 15 years of CA 125: what is known about the antigen, its structure and its function. Int J Biol Markers 1998;13: 188-195. (Pubitemid 29178547)
18. Welander CE. What do CA 125 and other antigens tell us about ovarian cancer biology? Acta Obstet Gynecol Scand Suppl 1992;155:85-93.
19. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers 1998;13:179-187. (Pubitemid 29178546)
20. Bischof P. What do we know about the origin of CA 125? Eur J Obstet Gynecol Reprod Biol 1993;49:93-98. (Pubitemid 23233189)
21. Turgut O, Tandogan I, Yilmaz MB, Gul I, Zorlu A. CA125 in heart failure: Implications for immunoinflammatory activity. Int J Cardiol 2011;146:99-100.
22. Halila H, Stenman UH, Seppala M. Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer 1986;57:1327-1329. (Pubitemid 16136749)
23. Barbieri RL, Niloff JM, Bast RC Jr, Scaetzl E, Kistner RW, Knapp RC. Elevated serum concentrations of CA-125 in patients with advanced endometriosis. Fertil Steril 1986;45:630-634. (Pubitemid 16112281)
24. Uzunkoy A, Harma M. Diagnosis of abdominal tuberculosis: experience from 11 cases and review of the literature. World J Gastroenterol 2004;10:3647-3649. (Pubitemid 39619285)
25. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009;361:170-177.
26. Bouanene H, Miled A. Tumor Marker CA125: biochemical and molecular properties. Bull Cancer 2009;96:597-601.
27. Burger RA, Darcy KM, DiSaia PJ, Monk BJ, Grosen EA, Gatanaga T, Granger GA, Wang J, Tian C, Hanjani P, Cohn DE. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study. Cancer 2004; 101:106-115. (Pubitemid 38812429)
28. Schmidt T, Rein DT, Foth D, Eibach HW, Kurbacher CM, Mallmann P, Römer T. Prognostic value of repeated serum CA 125 measurements in first trimester pregnancy. Eur J Obstet Gynecol Reprod Biol 2001;97:168-173. (Pubitemid 32651683)
29. Colakovic S, Lukic V, Mitrovic L, Jelic S, Susnjar S, Marinkovic J. Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers 2000;15: 147-152. (Pubitemid 30389362)
30. Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, Labrousse F, Voitot H. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999;45:1695-1707. (Pubitemid 29477325)
31. Hawkins RE, Roberts K, Wiltshaw E, Mundy J, McCready VR. The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma. Br J Cancer 1989;60:634-637. (Pubitemid 19251466)
32. Vizzardi E, Nodari S, D'Aloia A, Chiari E, Faggiano P, Metra M, Dei Cas L. CA 125 tumoral marker plasma levels relate to systolic and diastolic ventricular function and to the clinical status of patients with chronic heart failure. Echocardiography 2008;25:955-960.
33. Duman D, Palit F, Simsek E, Bilgehan K. Serum carbohydrate antigen 125 levels in advanced heart failure: relation to B-type natriuretic peptide and left atrial volume. Eur J Heart Fail 2008;10:556-559.
34. D'Aloia A, Faggiano P, Aurigemma G, Bontempi L, Ruggeri G, Metra M, Nodari S, Dei Cas L. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardio-graphic abnormalities, and short-term prognosis. J Am Coll Cardiol 2003;41: 1805-1811. (Pubitemid 36584256)
35. Kouris NT, Zacharos ID, Kontogianni DD, Goranitou GS, Sifaki MD, Grassos HE, Kalkandi EM, Babalis DK. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 2005;7:199-203. (Pubitemid 40215613)
36. Turk HM, Pekdemir H, Buyukberber S, Sevinc A, Camci C, Kocabas R, Tarakcioglu M, Buyukberber NM. Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 2003;24:172-175. (Pubitemid 37500565)
37. Nagele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rodiger W. CA 125 and its relation to cardiac function. Am Heart J 1999;137:1044-1049. (Pubitemid 30040726)
38. Kouris NT, Kontogianni DD, Papoulia EP, Goranitou GS, Zaharos ID, Grassos HA, Kalkandi EM, Sifaki MD, Babalis DK. Clinical and prognostic value of elevated CA125 levels in patients with congestive heart failure. Hellenic J Cardiol 2006;47:269-274. (Pubitemid 47621130)
39. Nunez J, Sanchis J, Bodi V, Fonarow GC, Nunez E, Bertomeu-Gonzalez V, Miñana G, Consuegra L, Bosch MJ, Carratalá A, Chorro FJ, Llàcer A. Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. Eur Heart J 2010;31:1752-1763.
40. Yilmaz MB, Zorlu A, Tandogan I. Plasma CA-125 level is related to both sides of the heart: a retrospective analysis. Int J Cardiol. doi:10.1016/j.ijcard.2009.12.003, published online ahead of print 2009 Dec 18.
41. Soma L, Allen M, Tobin L, Ganster C, Bulley M, Hunt J, Kricka LJ, Senior M, Kao A. CA-125 concentrations in patients awaiting cardiac transplantation. Clin Chem 2002;48:2289-2290. (Pubitemid 35397579)
42. Skórzyńska H, Solski J, Gernand W, Matras P, Gniwek M, Sokol M. Estimation of CA 125 concentration in patients with congestive heart failure. Ann Univ Mariae Curie Sklodowska Med 2004;59:261-264.
43. Nunez J, Nunez E, Consuegra L, Sanchis J, Bodi V, Martinez-Brotons A, Bertomeu-González V, Robles R, Bosch MJ, Fácila L, Darmofal H, Llàcer A. Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure? Heart 2007;93:716-721. (Pubitemid 46808274)
44. Mansour IN, Napan S, Tarek Alahdab M, Stamos TD. Carbohydrate antigen 125 predicts long-term mortality in African American patients with acute decompen-sated heart failure. Congest Heart Fail 2010;16:15-20.
45. Monteiro S, Franco F, Costa S, Monteiro P, Vieira H, Coelho L, Oliviera L, Providencia LA. Prognostic value of CA125 in advanced heart failure patients. Int J Cardiol 2010;140:115-118.
46. De Gennaro L, Brunetti ND, Bungaro R, Montrone D, Cuculo A, Pellegrino PL, Correale M, Di Biase M. Carbohydrate antigen-125: additional accuracy in identifying patients at risk of acute heart failure in acute coronary syndrome. Coron Artery Dis 2009;20:274-280.
47. Davies JR, Kirkham S, Svitacheva N, Thornton DJ, Carlstedt I. MUC16 is produced in tracheal surface epithelium and submucosal glands and is present in secretions from normal human airway and cultured bronchial epithelial cells. Int J Biochem Cell Biol 2007;39:1943-1954. (Pubitemid 47321352)
48. Yalta K, Yilmaz A, Turgut OO, Erselcan T, Yilmaz MB, Karadas F, Yontar OC, Tandogan I. Evaluation of tumor markers CA-125 and CEA in acute myocardial infarction. Adv Ther 2006;23:1052-1059. (Pubitemid 46341062)
49. Antonini-Canterin F, Popescu BA, Popescu AC, Beladan CC, Korcova R, Piazza R, Cappelletti P, Rubin D, Cassin M, Faggiano P, Nicolosi GL. Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. Int J Cardiol 2008;128:406-412.
50. Gupta S, Maheshwari A, Wuntkal R, Mazid T, Tongaonkar HB. Diagnostic dilemma in an elderly woman with intractable ascites and elevated CA-125 level. J Assoc Physicians India 2006;54:655-656. (Pubitemid 44222787)
51. Sugishita H, Imagawa H, Kawachi K, Takano S, Tsunooka N, Shikata F. Normalization of cancer antigen 125 after mitral valve replacement in a patient with congestive heart failure due to mitral valve endocarditis. Jpn J Thorac Cardiovasc Surg 2005; 53:486-489. (Pubitemid 41441890)
52. Mathew B, Bhatia V, Mahy IR, Ahmed I, Francis L. Elevation of the tumor marker CA125 in right heart failure. South Med J 2004;97:1013-1014. (Pubitemid 39391837)
53. Duman C, Ercan E, Tengiz I, Bozdemir H, Ercan HE, Nalbantgil I. Elevated serum CA 125 levels in mitral stenotic patients with heart failure. Cardiology 2003;100: 7-10. (Pubitemid 37140412)
54. Lockhart CJ, McVeigh GE, Harbinson MT. Elevated CA 125 and ascites: not always malignancy. Ir J Med Sci 2008;177:63-66.
55. Kosar F, Aksoy Y, Ozguntekin G, Ozerol I, Varol E. Relationship between cyto-kines and tumour markers in patients with chronic heart failure. Eur J Heart Fail 2006;8:270-274. (Pubitemid 44275312)
56. Minana G, Nunez J, Sanchis J, Bodi V, Nunez E, Llacer A. CA125 and immunoin-flammatory activity in acute heart failure. Int J Cardiol 2010;145:547-548.
57. Krack A, Sharma R, Figulla HR, Anker SD. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 2005;26:2368-2374. (Pubitemid 41552965)
58. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G, European Society of Cardiology; European Society of Intensive Care Medicine. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European society of cardiology and endorsed by the European society of intensive care medicine. Eur J Heart Fail 2010;12:423-433.
59. Ronco C, McCullough PA, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House A, Katz NM, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P, Acute Dialysis Quality Initiative (ADQI) consensus group. Cardior-enal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2010;165:54-67.
60. Turgut O, Tandogan I, Yilmaz MB, Gul I, Gurlek A. CA125 levels among patients with advanced heart failure: an emerging independent predictor for survival. Int J Cardiol 2010;145:71.
61. Zeimet AG, Offner FA, Marth C, Heim K, Feichtinger H, Daxenbichler G,Dapunt O. Modulation of CA-125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells. Anticancer Res 1997;17:3129-3131. (Pubitemid 27434874)
62. Field ME, Solomon SD, Lewis EF, Kramer DB, Baughman KL, Stevenson LW, Tedrow UB. Right ventricular dysfunction and adverse outcome in patients with advanced heart failure. J Card Fail 2006;12:616-620. (Pubitemid 44512147)
63. Refiker M, Yilmaz MB. Association of right heart with CA-125 levels in patients with heart failure. Int J Cardiol 2010;145:521-522.
64. Pencina MJ, D'Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 2010;48:1703-1711.